Processa Pharmaceuticals   Report issue

For profit Phase 1 Phase 2
Founded: Hanover MD United States (2009)

Organization Overview

First Clinical Trial
2018
NCT03836222
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Processa Pharmaceuticals

Active Ingredients

Drugs in Phase 2 Trials (2)

ctp-499 (3 trials)

pcs12852 (1 trial)

Drugs in Phase 1 Trials (3)

capecitabine (xeloda) (1 trial)

eniluracil (1 trial)

pentoxifylline (trental) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Necrobiosis Lipoidica (Phase 2)

Necrobiotic Disorders (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 5
  • # of Trial APIs: 5